Skip to main content

SITARE and SRISTI- GYTI FELLOWSHIP 2021 for Pharma and Lifesciences candidates

As in the previous years, this year also we are inviting the entries for SITARE - GYTI 2021 and SRISTI-GYTI 2021. In the last three years, GYTI awards was given by Honorable President Ram Nath Kovind at President house in 2018, Honorable Vice President Shri M. Venkaiah Naidu, in 2019 and by  Hon’ble Union Minister, Ministry of Health and Family Welfare, Science and Technology Dr Harsh Vardhan, in 2020.

All the eligible students should apply as earliest. The entries from life sciences can be submitted at the BIRAC website till Nov 30, 2020. However, all the entries of  non-life Science disciplines can be submitted at Gyti.techpedia.in or gyti.techpedia@sristi.org. The 15 awardees will get the funding of 15 lakhs.

Students Innovations for Translation & Advancement of Research Explorations (SITARE) Scheme is aimed at supporting innovative student projects in the area of biotechnology. The scheme’s mandate is to promote and encourage young students for embracing translational research to develop innovative products and technologies addressing unmet needs. SITARE-GYTI Award Grant is not a usual research fellowship. The scheme also provides an opportunity for orientation, training and mentoring through residential workshops etc.

SITARE-GYTI 2021

The scheme has two components:
SITARE-Gandhian Young Technological Innovation Award Grant(SITARE-GYTI): 15 innovative student projects will receive funding support of up to INR 15 lakhs each.  SITARE-GYTI encourages postgraduate and doctoral students to undertake projects with commercial potential leading to the creation of biotech startups. The fund recipients are recognized as BIRAC’s SITARE-GYTI beneficiaries.

Eligibility : Indian Students pursuing Ph.D/Masters* in any discipline# is eligible to apply for this award grant. The student should have a valid ID issued by the Institution/University. A No objection Certificate (NOC), as per the prescribed format needs to be submitted along with the application.

*Exceptions for exceptional talent: Meritorious candidature outside the above eligibility criteria maybe considered for SITARE with the approval of BIRAC’s competent authority.

#SITARE-GYTI award grant proposals can be submitted in any domain including Healthcare, Life sciences, Diagnostics, Medical Devices, Drugs, Vaccines, Drug Formulations and delivery systems, Industrial Biotechnology, Bioinformatics, Agriculture, Secondary agriculture, Waste Management, Sanitation, Clean Energy and Artificial Intelligence/IoT with application in any of these areas.

BIRAC encourages interdisciplinary proposals from any stream that can help conversion of innovative ideas into biotech products and technologies in any of the above fields

The full project report of the shortlisted projects will be needed for final evaluation. Video, photographs, test reports, comparative advantage, existing solutions in that domain, literature and patent review, etc., may be sent along with the full project report.

SITARE-Appreciation Grant : Residential workshops called as Biotech Innovation Ignition School (BIIS) for undergraduate students are organized to provide hands-on technical training and mentorship for problem identification in 3-4 weeks duration. Out of 30-40 students per workshop, 10 students are selected and provided grant support of up to INR 1 lakh each to encourage their inquisitiveness and sustained efforts. The recipients are recognized as BIRAC’s SITARE-Appreciation beneficiaries. In a year, 3 such workshops are conducted. Applications for SITARE-GYTI Award Grants and BIIS workshop participation are invited at national level.

Eligibility :
Students pursuing Bachelors programme in any discipline, preferably from Tier II/Tier III cities and aspirational districts within India. The student should have a valid ID issued by the Institution/University.

A student can avail only one opportunity for BIIS workshop training across all SITARE Partners, except for the SITARE-Appreciation Award Grantees who will be eligible to avail access to subsequent workshops by other Partners on recommendation by SITARE Partner/BIRAC.

APPLY ONLINE>>


SRISTI-GYTI 2021

SRISTI-GYTI (Gandhian Young Technological Innovation) Awards, 2021 for technology students from all disciplines of Engineering/technology except for life sciences

The awards will be given to young student innovators in the following category:
• MLM (More from less for many), Frugal Innovation award- technologies that economise on the use of materials/energy, are extremely sustainable
• SRISTI - socially relevant technological innovation award-products/prototypes that address unmet social needs or improve the functioning of existing solutions, increase affordability and/or improve circularity i.e. ecological compatibility.
• Technological-edge award-ideas that push the frontiers in any technological domain.

Student projects which address an important social, environmental or technological problem faced by masses or disadvantaged people/sectors/spaces or micro and small enterprises, or have the potential to impact a pressing national need are invited. The applications may be made by the past or present students of technical institutions/universities. The faculty member, who supervised the project, can also apply on behalf of the students who have already passed out and left the Institute/ University, but awards would be given only to students willing to take their ideas forward. No financial grant accompanies these awards, only citations are given to recognize the talent of young innovators.

Eligibility : An Indian Student pursuing  UG/PG/PhD in any discipline is eligible to apply for this award. The student should have a valid ID issued by the Institution/University. A No objection Certificate (NOC), as per the prescribed format needs to be submitted along with the application.

The full project report of the shortlisted projects will be needed for final evaluation. Video, photographs, test reports, comparative advantage vis a vis existing solutions in that domain, literature & patent review, etc., may be attached.

APPLY ONLINE>>

For any query, please Contact Team Techpedia-GYTI at gyti.techpedia@sristi.org or Call us at +919099258492

The last date for submission of entries is 30 November 2020

Job opening for Pharmacy Manager, Pharmacist at AIIA | Govt. of India

All India Institute of Ayurveda (AIIA) is a new up-coming Institute as Autonomous Organization under the aegis of Ministry of AYUSH, Govt. of India. Institute imparts postgraduate, doctoral, post-doctoral and Super-specialty Fellowship Programmes in major streams of Ayurveda. All India Institute of Ayurveda acts as a referral hospital and a “Centre of Excellence” to set highest standards of education, research, patient care and also functions as a model center for international collaboration.

Career for Pharmacists at Regional Ayurveda Research Centre

The institute was established as ”Regional Research Institute (Ayurveda)“ on February 19, 1981 as peripheral unit under the Central Council For Research in Ayurveda and Siddha (CCRAS) and started functioning along with the facilities of OPD, IPD and Mobile Clinical Research Unit (MCRU) Pathology and Bio chemistry Laboratory at Lucknow. The institute was upgraded and renamed as “Central Research Institute (Ayurveda)” on February 1997 by merging various units.

Post : Pharmacist

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer (ES-SCLC) and will be available to patients weighing more than 30kg as an alternative to the approved weight-based dosing of 10mg/kg every two weeks.

The approval by the Food and Drug Administration (FDA) was based on data from several Imfinzi clinical trials, including the PACIFIC Phase III trial which supported the two-week, weight-based dosing in unresectable Stage III NSCLC, and the CASPIAN Phase III trial which used four-week, fixed-dosing during maintenance treatment in ES-SCLC. The decision follows the Priority Review granted by the FDA in August 2020.

Victoria M. Villaflor, MD, Clinical Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Cancer Center, Los Angeles, California, said: “This new four-week dosing option gives doctors the choice to cut the number of visits for critical cancer treatment in half and offers a regimen that is more convenient for patients. Additionally, it limits potential exposure to infection in the healthcare environment for a population that is especially vulnerable to complications from COVID-19.”

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “The approval of this new dosing option across indications reflects our ongoing commitment to improve the patient experience and ensure continuity of care - a priority at all times, but especially during the pandemic. Cancer won’t wait, and it is our job to provide patients with treatment options that acknowledge the challenges the pandemic poses to cancer care, enabling them to visit their physician when truly needed and avoid preventable exposure to healthcare-associated infections.”


The four-week 1,500mg fixed-dosing option for Imfinzi is also under regulatory review in several other countries, including in the EU where the new dosing option was granted accelerated assessment.

Imfinzi is approved in the curative-intent setting of unresectable, Stage III NSCLC after CRT in the US, in the EU, in Japan, in China and in many other countries, based on the PACIFIC Phase III trial. Imfinzi is also approved for previously treated patients with advanced bladder cancer in the US and several other countries. Additionally, it is approved in the US, the EU, Japan and several other countries around the world for the treatment of ES-SCLC based on the CASPIAN Phase III trial.


<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

Recruitment for Pharmacists (03 posts) under Central Government Health Scheme

Applications are invited from the retirees of State/Central Govt/Defence Serivces/ABI to fillup the vacant posts as per details given below purely on contract basis for a period of 180 days only.

Career for Pharmacist at PGIMER

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

Subscribe to